Cabenuva administered every other month suppresses HIV for at least two years. The regimen consists of an extended-release formulation of ViiV Healthcare’s integrase inhibitor cabotegravir plus an injectable version of Janssen’s non-nucleoside reverse transcriptase inhibitor rilpivirine. The Food and Drug Administration (FDA) recently approved Cabenuva as a monthly regimen, but European regulators also gave the nod to an every-other-month schedule. The ATLAS-2M trial showed that once-monthly and every-other-month dosing are equally effective. After 96 weeks, 90% of people in the once-monthly group and 91% in the every-other-month group maintained viral suppression. But sticking to the schedule is especially important for those using Cabenuva every other month. Studies showed that delaying cabotegravir or rilpivirine injections by up to a week should have little impact, but longer delays could be a problem. ViiV has requested FDA approval of the every-other-month regimen.
Treatment: Every Two Months
Study finds that Cabenuva administered every other month maintains viral suppression for two years.